ICU Medical Inc.
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree connector products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoLock and ChemoClave closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs. It also provides IV therapy and diluents, including sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation, such as sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. In addition, the company offers infusion pumps under the Plum 360 and LifeCare PCA brands; IV mediation safety software, including ICU Medical Mednet, an enterprise medication management platform that connects smart pumps to hospital's electronic health records, asset tracking systems, and alarm notification platforms; and related professional services. Further, it provides critical care products comprising Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems; TDQ and OptiQ cardiac output monitoring catheters; TriOx venous oximetry catheters; Transpac blood pressure transducers; and SafeSet closed blood sampling and conservation systems. The company sells its products to acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is headquartered in San Clemente, California.
IPO Year: 1992
Exchange: NASDAQ
Website: icumed.com
Peers
Recent Analyst Ratings for ICU Medical Inc.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/12/2025 | $205.00 → $197.00 | Outperform → Strong Buy | Raymond James |
| 12/11/2024 | $200.00 | Hold → Buy | Jefferies |
| 10/14/2024 | $183.00 | Hold | Jefferies |
| 6/21/2024 | Hold | Needham | |
| 6/17/2024 | $135.00 | Mkt Perform → Outperform | Raymond James |
| 11/8/2022 | Outperform → Mkt Perform | Raymond James | |
| 2/28/2022 | $286.00 → $265.00 | Outperform | Raymond James |
| 10/22/2021 | $302.00 → $280.00 | Overweight | Keybanc |
| 9/9/2021 | $220.00 → $286.00 | Outperform | Raymond James |
| 9/9/2021 | $225.00 → $302.00 | Overweight | Keybanc |
ICU Medical Inc. Press Releases
Fastest customizable press release news feed in the world
ICU Medical to Present at the 24th Annual Needham Virtual Healthcare Conference
SAN CLEMENTE, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- ICU Medical (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will present at the 24th Annual Needham Virtual Healthcare Conference being held April 7-10, 2025. ICU Medical's presentation will be on Monday, April 7, 2025 at 8:00 a.m. PT (11:00 a.m. ET). Company management will also be participating in one-on-one meetings on Monday, April 7, 2025. The presentation will be webcast live and can be accessed by going to the Company's website at http://www.icumed.com, clicking on the Investors tab and clicking on the Event Calendar tab. The webcast will
ICU Medical to Participate at the KeyBanc Healthcare Forum
SAN CLEMENTE, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- ICU Medical (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will participate in a fireside chat at the KeyBanc Healthcare Forum being held virtually, March 18-19, 2025. ICU Medical's fireside chat will be on Wednesday, March 19, 2025 at 8:15 a.m. PT (11:15 a.m. ET). Company management will also be participating in one-on-one meetings on Wednesday, March 19, 2025. The fireside chat will be webcast live and can be accessed by going to the Company's website at http://www.icumed.com, clicking on the Investors tab and clicking on the Event Calendar
ICU Medical Announces Fourth Quarter 2024 Results and Provides Fiscal Year 2025 Guidance
SAN CLEMENTE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended December 31, 2024. Fourth Quarter 2024 Results Fourth quarter 2024 revenue was $629.8 million, as compared to $587.9 million in the same period in the prior year. GAAP gross profit for the fourth quarter of 2024 was $227.3 million, as compared to $171.6 million in the same period in the prior year. GAAP gross margin for the fourth quarter of 2024 was 36.1%, as compared to 29.2% in the same period in the prior year. GAAP net loss for the fourth quarter of 2
ICU Medical to Present at the Raymond James 46th Annual Institutional Investors Conference
SAN CLEMENTE, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- ICU Medical (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will present at the Raymond James 46th Annual Institutional Investors Conference being held in Orlando, Florida, March 3-5, 2025. ICU Medical's presentation will be on Monday, March 3, 2025 at 5:40 a.m. PT (8:40 a.m. ET). Company management will also be participating in one-on-one meetings on Monday, March 3, 2025. The presentation will be webcast live and can be accessed by going to the Company's website at http://www.icumed.com, clicking on the Investors tab and clicking on the Event C
ICU Medical Announces Time of Fourth Quarter 2024 Earnings Conference Call
SAN CLEMENTE, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its fourth quarter 2024 earnings release and conference call. The Company will release its fourth quarter 2024 results on Thursday, February 27, 2025 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Thursday, February 27, 2025. The call can be accessed at (800) 445-7795, conference ID "ICUMED". The conference call will be simultaneously available by webcast, which can be accessed by going to the Com
ICU Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SAN CLEMENTE, Calif., Jan. 03, 2025 (GLOBE NEWSWIRE) -- ICU Medical (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will present at the 43rd Annual J.P. Morgan Healthcare Conference being held in San Francisco, California, January 13-16, 2025. ICU Medical's presentation will be on Wednesday, January 15, 2025 at 10:30 a.m. PT (1:30 p.m. ET). Company management will also be participating in one-on-one meetings on Wednesday, January 15, 2025 and Thursday, January 16, 2025. The presentation will be webcast live and can be accessed by going to the Company's website at http://www.icumed.com, clicking on the
ICU Medical, Inc. and Otsuka Pharmaceutical Factory, Inc., a Subsidiary of Otsuka Holdings Co. Ltd., Announce Creation of a Joint Venture to Bolster IV Solutions Manufacturing and Innovation in North America
The partnership creates one of the largest global IV solutions manufacturing networks with combined production of an estimated 1.4 billion annual units and aims to bring additional supply chain resiliency and new innovation to the North American IV solutions market. Joint venture becomes part of a global manufacturing network with scale and redundancyIntends to add long-term supply resiliency and accelerate IV solutions new product development in North AmericaCombines Otsuka Pharmaceutical Factory, Inc.'s expertise and global manufacturing scale with ICU Medical's strong North American production and distributionICU Medical to provide commercial services to the joint ventureExpected to becom
ICU Medical Announces Third Quarter 2024 Results and Updates Its Fiscal Year 2024 Guidance
SAN CLEMENTE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended September 30, 2024. Third Quarter 2024 Results Third quarter 2024 revenue was $589.1 million, as compared to $553.3 million in the same period in the prior year. GAAP gross profit for the third quarter of 2024 was $204.9 million, as compared to $183.9 million in the same period in the prior year. GAAP gross margin for the third quarter of 2024 was 34.8%, as compared to 33.2% in the same period in the prior year. GAAP net loss for the third quarter of 2024
ICU Medical to Participate at the UBS Global Healthcare Conference
SAN CLEMENTE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- ICU Medical (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will present at the UBS Global Healthcare Conference being held in Rancho Palos Verdes, California, November 11-14, 2024. ICU Medical's presentation will be on Wednesday, November 13, 2024 at 4:15 p.m. PT (7:15 p.m. ET). Company management will also be participating in one-on-one meetings on Wednesday, November 13, 2024. The presentation will be webcast live and can be accessed by going to the Company's website at http://www.icumed.com, clicking on the Investors tab and clicking on the E
ICU Medical Announces Time of Third Quarter 2024 Earnings Conference Call
SAN CLEMENTE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its third quarter 2024 earnings release and conference call. The Company will release its third quarter 2024 results on Tuesday, November 12th, 2024 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Tuesday, November 12th, 2024. The call can be accessed at (800) 343-5172, conference ID "ICUMED". The conference call will be simultaneously available by webcast, which can be accessed by going to the Com
ICU Medical Inc. Analyst Ratings
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
ICU Medical upgraded by Raymond James with a new price target
Raymond James upgraded ICU Medical from Outperform to Strong Buy and set a new price target of $197.00 from $205.00 previously
ICU Medical upgraded by Jefferies with a new price target
Jefferies upgraded ICU Medical from Hold to Buy and set a new price target of $200.00
Jefferies initiated coverage on ICU Medical with a new price target
Jefferies initiated coverage of ICU Medical with a rating of Hold and set a new price target of $183.00
Needham initiated coverage on ICU Medical
Needham initiated coverage of ICU Medical with a rating of Hold
ICU Medical upgraded by Raymond James with a new price target
Raymond James upgraded ICU Medical from Mkt Perform to Outperform and set a new price target of $135.00
ICU Medical downgraded by Raymond James
Raymond James downgraded ICU Medical from Outperform to Mkt Perform
Raymond James reiterated coverage on ICU Medical with a new price target
Raymond James reiterated coverage of ICU Medical with a rating of Outperform and set a new price target of $265.00 from $286.00 previously
Keybanc reiterated coverage on ICU Medical with a new price target
Keybanc reiterated coverage of ICU Medical with a rating of Overweight and set a new price target of $280.00 from $302.00 previously
Raymond James reiterated coverage on ICU Medical with a new price target
Raymond James reiterated coverage of ICU Medical with a rating of Outperform and set a new price target of $286.00 from $220.00 previously
Keybanc reiterated coverage on ICU Medical with a new price target
Keybanc reiterated coverage of ICU Medical with a rating of Overweight and set a new price target of $302.00 from $225.00 previously
ICU Medical Inc. Insider Trading
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
Chief Financial Officer Bonnell Brian Michael converted options into 3,248 shares, increasing direct ownership by 12% to 30,348 units (SEC Form 4)
4 - ICU MEDICAL INC/DE (0000883984) (Issuer)
Chairman and CEO Jain Vivek converted options into 4,872 shares and covered exercise/tax liability with 2,688 shares, increasing direct ownership by 2% to 108,220 units (SEC Form 4)
4 - ICU MEDICAL INC/DE (0000883984) (Issuer)
VP, General Counsel Sanzone Virginia Ruth converted options into 1,624 shares and covered exercise/tax liability with 898 shares, increasing direct ownership by 11% to 7,086 units (SEC Form 4)
4 - ICU MEDICAL INC/DE (0000883984) (Issuer)
Chief Information Officer Sousa Ben converted options into 1,299 shares and covered exercise/tax liability with 716 shares, increasing direct ownership by 31% to 2,479 units (SEC Form 4)
4 - ICU MEDICAL INC/DE (0000883984) (Issuer)
Chief Operating Officer Voigtlander Christian B. converted options into 3,248 shares and covered exercise/tax liability with 1,792 shares, increasing direct ownership by 156% to 2,389 units (SEC Form 4)
4 - ICU MEDICAL INC/DE (0000883984) (Issuer)
VP, GM-Infusion Capital Woolson Daniel covered exercise/tax liability with 1,294 shares and converted options into 2,923 shares, increasing direct ownership by 13% to 14,194 units (SEC Form 4)
4 - ICU MEDICAL INC/DE (0000883984) (Issuer)
SEC Form 4 filed by Chairman and CEO Jain Vivek
4 - ICU MEDICAL INC/DE (0000883984) (Issuer)
VP, General Counsel Sanzone Virginia Ruth converted options into 4,262 shares and covered exercise/tax liability with 2,384 shares, increasing direct ownership by 42% to 6,360 units (SEC Form 4)
4 - ICU MEDICAL INC/DE (0000883984) (Issuer)
Chairman and CEO Jain Vivek converted options into 3,218 shares and covered exercise/tax liability with 1,775 shares, increasing direct ownership by 1% to 106,036 units (SEC Form 4)
4 - ICU MEDICAL INC/DE (0000883984) (Issuer)
Chief Information Officer Sousa Ben covered exercise/tax liability with 810 shares and converted options into 1,387 shares, increasing direct ownership by 44% to 1,896 units (SEC Form 4)
4 - ICU MEDICAL INC/DE (0000883984) (Issuer)
ICU Medical Inc. SEC Filings
SEC Form 10-K filed by ICU Medical Inc.
10-K - ICU MEDICAL INC/DE (0000883984) (Filer)
ICU Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - ICU MEDICAL INC/DE (0000883984) (Filer)
SEC Form 10-Q filed by ICU Medical Inc.
10-Q - ICU MEDICAL INC/DE (0000883984) (Filer)
ICU Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - ICU MEDICAL INC/DE (0000883984) (Filer)
ICU Medical Inc. filed SEC Form 8-K: Leadership Update
8-K - ICU MEDICAL INC/DE (0000883984) (Filer)
SEC Form 10-Q filed by ICU Medical Inc.
10-Q - ICU MEDICAL INC/DE (0000883984) (Filer)
ICU Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - ICU MEDICAL INC/DE (0000883984) (Filer)
SEC Form SD filed by ICU Medical Inc.
SD - ICU MEDICAL INC/DE (0000883984) (Filer)
ICU Medical Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
8-K - ICU MEDICAL INC/DE (0000883984) (Filer)
SEC Form 10-Q filed by ICU Medical Inc.
10-Q - ICU MEDICAL INC/DE (0000883984) (Filer)
ICU Medical Inc. FDA approvals
Live FDA approvals issued by the Food and Drug Administration and FDA breaking news
FDA Approval for POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER issued to ICU MEDICAL INC
Submission status for ICU MEDICAL INC's drug POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER (SUPPL-8) with active ingredient POTASSIUM CHLORIDE; SODIUM CHLORIDE has changed to 'Approval' on 05/15/2023. Application Category: ANDA, Application Number: 078446, Application Classification: Labeling
ICU Medical Inc. Leadership Updates
Live Leadership Updates
Carlyle Group and WP Carey Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600
NEW YORK, Nov. 27, 2023 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600 effective prior to the open of trading on Thursday, November 30: Carlyle Group Inc. (NASD: CG) will replace ICU Medical Inc. (NASD: ICUI) in the S&P MidCap 400. ICU Medical will replace PacWest Bancorp (NASD: PACW) in the S&P SmallCap 600. Banc of California Inc. (NYSE:BANC) is acquiring PacWest Bancorp in a deal expected to be completed soon, pending final closing conditions. Post-merger, Banc of California will remain in the S&P SmallCap 600. ICU Medical is more representative of the small-cap market space.WP Carey Inc. (NYSE: WPC) will replace Worthingt
ICU Medical Inc. Financials
Live finance-specific insights
ICU Medical Announces Fourth Quarter 2024 Results and Provides Fiscal Year 2025 Guidance
SAN CLEMENTE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended December 31, 2024. Fourth Quarter 2024 Results Fourth quarter 2024 revenue was $629.8 million, as compared to $587.9 million in the same period in the prior year. GAAP gross profit for the fourth quarter of 2024 was $227.3 million, as compared to $171.6 million in the same period in the prior year. GAAP gross margin for the fourth quarter of 2024 was 36.1%, as compared to 29.2% in the same period in the prior year. GAAP net loss for the fourth quarter of 2
ICU Medical Announces Time of Fourth Quarter 2024 Earnings Conference Call
SAN CLEMENTE, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its fourth quarter 2024 earnings release and conference call. The Company will release its fourth quarter 2024 results on Thursday, February 27, 2025 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Thursday, February 27, 2025. The call can be accessed at (800) 445-7795, conference ID "ICUMED". The conference call will be simultaneously available by webcast, which can be accessed by going to the Com
ICU Medical Announces Third Quarter 2024 Results and Updates Its Fiscal Year 2024 Guidance
SAN CLEMENTE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended September 30, 2024. Third Quarter 2024 Results Third quarter 2024 revenue was $589.1 million, as compared to $553.3 million in the same period in the prior year. GAAP gross profit for the third quarter of 2024 was $204.9 million, as compared to $183.9 million in the same period in the prior year. GAAP gross margin for the third quarter of 2024 was 34.8%, as compared to 33.2% in the same period in the prior year. GAAP net loss for the third quarter of 2024
ICU Medical Announces Time of Third Quarter 2024 Earnings Conference Call
SAN CLEMENTE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its third quarter 2024 earnings release and conference call. The Company will release its third quarter 2024 results on Tuesday, November 12th, 2024 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Tuesday, November 12th, 2024. The call can be accessed at (800) 343-5172, conference ID "ICUMED". The conference call will be simultaneously available by webcast, which can be accessed by going to the Com
ICU Medical Announces Second Quarter 2024 Results and Updates Its Fiscal Year 2024 Guidance
SAN CLEMENTE, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended June 30, 2024. Second Quarter 2024 Results Second quarter 2024 revenue was $596.5 million, compared to $549.3 million in the same period in the prior year. GAAP gross profit for the second quarter of 2024 was $207.4 million, as compared to $192.3 million in the same period in the prior year. GAAP gross margin for the second quarter of 2024 and 2023 was 35%. GAAP net loss for the second quarter of 2024 was $(21.4) million, or $(0.88) per diluted share, as c
ICU Medical Announces Time of Second Quarter 2024 Earnings Conference Call
SAN CLEMENTE, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its second quarter 2024 earnings release and conference call. The Company will release its second quarter 2024 results on Wednesday, August 7th, 2024 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Wednesday, August 7th, 2024. The call can be accessed at (800) 579-2543, conference ID "ICUMED". The conference call will be simultaneously available by webcast, which can be accessed by going to the C
ICU Medical Announces First Quarter 2024 Results
SAN CLEMENTE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended March 31, 2024. First Quarter 2024 Results First quarter 2024 revenue was $566.7 million, compared to $568.6 million in the same period in the prior year. GAAP gross profit for the first quarter of 2024 was $185.2 million, as compared to $192.0 million in the same period in the prior year. GAAP gross margin for the first quarter of 2024 was 33%, as compared to 34% in the same period in the prior year. GAAP net loss for the first quarter of 2024 was $(39.5)
ICU Medical Announces Time of First Quarter 2024 Earnings Conference Call
SAN CLEMENTE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its first quarter 2024 earnings release and conference call. The Company will release its first quarter 2024 results on Tuesday, May 7th, 2024 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Tuesday, May 7th, 2024. The call can be accessed at (800) 717-1738, conference ID 1112534. The conference call will be simultaneously available by webcast, which can be accessed by going to the Company's websi
ICU Medical Announces Fourth Quarter 2023 Results and Provides Fiscal Year 2024 Guidance
SAN CLEMENTE, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarter ended December 31, 2023. Fourth Quarter 2023 Results Fourth quarter 2023 revenue was $587.9 million, compared to $578.0 million in the same period in the prior year. GAAP gross profit for the fourth quarter of 2023 was $171.6 million, as compared to $174.9 million in the same period in the prior year. GAAP gross margin for the fourth quarter of 2023 was 29%, as compared to 30% in the same period in the prior year. GAAP net loss for the fourth quarter of 2023
ICU Medical Announces Time of Fourth Quarter 2023 Earnings Conference Call
SAN CLEMENTE, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its fourth quarter 2023 earnings release and conference call. The Company will release its fourth quarter 2023 results on Tuesday, February 27th, 2024 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Tuesday, February 27th, 2024. The call can be accessed at (833) 816-1376, conference ID 10186026. The conference call will be simultaneously available by webcast, which can be accessed by going to the
ICU Medical Inc. Large Ownership Changes
This live feed shows all institutional transactions in real time.
Amendment: SEC Form SC 13G/A filed by ICU Medical Inc.
SC 13G/A - ICU MEDICAL INC/DE (0000883984) (Subject)
Amendment: SEC Form SC 13G/A filed by ICU Medical Inc.
SC 13G/A - ICU MEDICAL INC/DE (0000883984) (Subject)
Amendment: SEC Form SC 13D/A filed by ICU Medical Inc.
SC 13D/A - ICU MEDICAL INC/DE (0000883984) (Subject)
SEC Form SC 13G filed by ICU Medical Inc.
SC 13G - ICU MEDICAL INC/DE (0000883984) (Subject)
SEC Form SC 13G/A filed by ICU Medical Inc. (Amendment)
SC 13G/A - ICU MEDICAL INC/DE (0000883984) (Subject)
SEC Form SC 13G/A filed by ICU Medical Inc. (Amendment)
SC 13G/A - ICU MEDICAL INC/DE (0000883984) (Subject)
SEC Form SC 13G/A filed by ICU Medical Inc. (Amendment)
SC 13G/A - ICU MEDICAL INC/DE (0000883984) (Subject)
SEC Form SC 13G/A filed by ICU Medical Inc. (Amendment)
SC 13G/A - ICU MEDICAL INC/DE (0000883984) (Subject)
SEC Form SC 13G/A filed by ICU Medical Inc. (Amendment)
SC 13G/A - ICU MEDICAL INC/DE (0000883984) (Subject)
SEC Form SC 13G filed by ICU Medical Inc.
SC 13G - ICU MEDICAL INC/DE (0000883984) (Subject)